Nonalcoholic steatohepatitis (NASH) is a progressive form of fatty liver disease characterized by excess fat accumulation, inflammation, and liver cell injury. It is now referred to as metabolic dysfunction-associated steatohepatitis (MASH) under updated liver disease terminology.

NASH can progress from liver inflammation to fibrosis, cirrhosis, and other serious complications.

At Bay Biosciences, we provide high-quality NASH Plasma Samples and other biospecimens, including Fatty Liver Disease Samples, Liver Disease Plasma Samples, Serum & Plasma samples, etc to support research, diagnostics, biomarker discovery, and drug development.

Understanding Nonalcoholic Steatohepatitis (NASH)

Nonalcoholic steatohepatitis is a form of nonalcoholic fatty liver disease (NAFLD), now commonly classified within metabolic dysfunction-associated steatotic liver disease (MASLD).

Unlike simple fatty liver, NASH involves both fat accumulation and inflammation or liver cell injury.

NASH can develop when metabolic factors contribute to excess fat storage in the liver.

Persistent inflammation can damage liver cells and promote fibrosis, or scarring. In advanced cases, fibrosis can progress to cirrhosis and increase the risk of liver failure and liver cancer.

Researchers study Nonalcoholic Steatohepatitis Plasma Samples to investigate circulating biomarkers associated with inflammation, liver injury, metabolic dysfunction, fibrosis, and disease progression.

NASH Plasma Samples

Signs and Symptoms of NASH

NASH often develops without noticeable symptoms, particularly during its early stages. Many individuals may not know they have liver disease until routine blood tests or imaging reveal abnormalities.

As liver disease progresses, patients may experience:

Researchers can use clinical information associated with Liver Disease Plasma Samples to investigate relationships between circulating biomarkers, symptoms, and disease severity.

Causes and Risk Factors of NASH

Several metabolic and genetic factors can increase the risk of developing the disease.

Obesity

Overweight and obesity are strongly associated with fatty liver disease and metabolic dysfunction. Excess adipose tissue can contribute to metabolic changes that promote fat accumulation and inflammation in the liver.

Insulin Resistance and Type 2 Diabetes

Insulin resistance and type 2 diabetes can increase the likelihood of developing fatty liver disease and NASH. Abnormal glucose and insulin metabolism can contribute to fat accumulation in the liver.

Abnormal Blood Lipids

High triglyceride levels and abnormal cholesterol levels can also increase the risk of metabolic dysfunction-associated liver disease.

Metabolic Syndrome

Metabolic syndrome combines several risk factors, including abdominal obesity, abnormal blood lipids, high blood pressure, and elevated blood glucose. These conditions can increase the likelihood of developing MASLD and MASH.

Genetic and Environmental Factors

Genes, diet, physical activity, and other environmental factors may also influence an individual’s risk.

Researchers continue to investigate how these factors interact with metabolic pathways and the liver’s response to excess fat.

These relationships make NASH an important area of metabolic disease research.

Diagnosis of Nonalcoholic Steatohepatitis

Healthcare professionals use medical history, physical examination, blood tests, imaging, and sometimes liver biopsy to evaluate fatty liver disease.

Blood Tests

Blood testing can help evaluate liver enzymes and identify metabolic abnormalities.

Researchers can also analyze blood-derived specimens to investigate circulating biomarkers associated with liver injury and disease progression.

Imaging Studies

Ultrasound, computed tomography (CT), and magnetic resonance imaging (MRI) can help identify fat accumulation in the liver. Elastography can also help assess liver stiffness and provide information about fibrosis.

Liver Biopsy

A liver biopsy allows pathologists to examine liver tissue for steatosis, inflammation, hepatocyte injury, and fibrosis.

Treatment of NASH

Treatment focuses on reducing metabolic risk factors and limiting liver damage.

Lifestyle changes can improve fatty liver disease, particularly in individuals who are overweight or obese.

Common management strategies include:

Applications of NASH Plasma Samples

Researchers use NASH Plasma Samples in a variety of scientific and clinical applications.

Biomarker Discovery

Researchers analyze plasma to identify potential biomarkers associated with liver injury, inflammation, fibrosis, and disease progression. Fatty Liver Disease Samples can support the discovery and validation of circulating biomarkers.

Metabolic Disease Research

Because NASH is closely associated with obesity, insulin resistance, type 2 diabetes, and metabolic syndrome, researchers use Metabolic Disease Samples to investigate relationships between metabolic dysfunction and liver disease.

Liver Disease Research

Liver Disease Plasma Samples can help scientists compare circulating molecular profiles across different liver conditions. Researchers may investigate proteins, metabolites, inflammatory mediators, and other biological markers associated with liver injury.

Drug Discovery and Development

Pharmaceutical researchers can use plasma specimens to evaluate potential therapeutic targets, investigate treatment response, and monitor changes in disease-associated biomarkers during drug development.

Precision Medicine

Researchers can combine molecular information from plasma with clinical and genetic data to investigate why patients experience different disease trajectories or responses to treatment.

FAQs

What is the difference between NASH and MASH?

NASH stands for nonalcoholic steatohepatitis, while MASH stands for metabolic dysfunction-associated steatohepatitis. MASH is the newer terminology introduced as part of the updated classification of fatty liver disease.

Why are Human Plasma Samples useful in liver disease research?

Human Plasma Samples contain circulating biological molecules that researchers can analyze to investigate disease-associated changes and potential biomarkers.

What are Fatty Liver Disease Samples used for?

Researchers use Fatty Liver Disease Samples to investigate disease mechanisms, metabolic pathways, biomarkers, fibrosis, inflammation, disease progression, and potential therapeutic targets.

Are NASH Plasma Samples collected ethically?

Yes. All biospecimens are ethically collected under IRB-approved protocols with informed consent and complete donor de-identification.

Supporting Your Research with Bay Biosciences

At Bay Biosciences, we provide high-quality biospecimens to support research into MASH, fatty liver disease, and related metabolic disorders.

Our comprehensive range of biospecimens includes:

If you have any questions, concerns, or special requests, please don’t hesitate to contact us.